| Summary: | 碩士 === 國立臺北科技大學 === 有機高分子研究所 === 100 === According to fatality statistics in 2011, cancer is one of the leading causes of death while the incidence of colon cancer is the number third. The treatment methods of cancers include surgery, radiation therapy and chemical anti-cancer drugs. However, the surgery and radiation therapy are known with higher risks, the alternative treatment uses the specificity of the anti-cancer drugs to inhibit cancer cell proliferation. SRC and mTOR both play important roles in regulating cell growth, protein translation, metabolism and cell signaling. SRC is an oncogene, whereas mTOR is a target of anti-cancer drugs. SRC also plays a critical role in the regulation of mTOR signaling pathway. We used rapamycin, an mTOR inhibitor and saracatinib, an SRC inhibitor to elucidate a new anti-cancer chemical compound (3228) and understand the inhibition of the pathway.
First of all, our laboratory has been screened a chemical compound (3228) that showed inhibition on the survival rate of human colon cancer cells(DLD-1). We tested the cell proliferation in DLD-1 by using different concentrations and times. The result showed that 3228 has significant inhibition on the survival rate of DLD-1. Moreover, we explored the impact on SRC and mTOR in DLD-1 tested 3228. The real-time qPCR results showed that SRC gene is relatively decease in comparing compared with the control group without adding of the compound. Moreover, using western blot to measure the protein expression of SRC and mTOR, the result indicated that the SRC and mTOR protein both decreased after adding 3228. As a summary, the chemical compound (3228) can developed as an potential anti-cancer drug.
|
|---|
